Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials

By afschroeder • September 22, 2025

Gold LS, Armstrong AW, Bissonnette R, Magnolo N, Vender RB, Sebastian M, Galimberti ML, Tsianakas A, Arnone M, Wallace P, Simon M, Riera-Monroig J, Gerdes S, Waibel J, Gonzalez-Cantero A, Schwarz B, Tada Y, Cecchini M, Ehst B, Kircik L, Kephart L, Reyes-Servin O, Edem BE, Campbell JH, Shen YK, Cresswell K, Li S, DeKlotz CMC, Nunes F, Papp KA. Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials. Lancet. 2025 Sep 18:S0140-6736(25)01576-4. doi: 10.1016/S0140-6736(25)01576-4. Epub ahead of print. PMID: 40976249.

Tags: Dermatology, Publications

Epidermotropic Metastatic Prostate Adenocarcinoma With Florid Squamous Transformation/Differentiation and Associated Acantholysis. An Unusual Clinicopathologic Entity

Hoffman SJ, Sadrolashrafi K, Mobini N. Epidermotropic Metastatic Prostate Adenocarcinoma With Florid Squamous Transformation/Differentiation and Associated Acantholysis. An Unusual Clinicopathologic Entity. Case Rep Dermatol Med.[...]

Prediction Markets in Dermatology: Ethical Considerations for Physicians

Jonnalagadda A, Desai AD, Zhou AE, Grant-Kels JM. Prediction Markets in Dermatology: Ethical Considerations for Physicians. Clin Dermatol. 2026 Sep 3:S0738-081X(26)00226-9. doi: 10.1016/j.clindermatol.2026.09.001. Epub ahead[...]

Delphi Consensus Statement on Treatment of Severe Alopecia Areata in US Adults

Gregoire S, Dewey E, Biba U, Sanchez K, Englander H, Salloum L, Ershadi S, Cheng D, McIntosh BA, Zangenah N, Vazquez-Machado M, Parekh A, Kam[...]